Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (NASDAQ:RGEN) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Repligen's business and see what CAPS investors are saying about the stock right now.

Repligen facts

Headquarters (Founded)

Waltham, Mass. (1981)

Market Cap

$119.0 million

Industry

Biotechnology

Trailing-12-Month Revenue

$21.1 million

Management

CEO Dr. Walter Herlihy

CFO William Kelly

Compound Annual Revenue Growth (Over Past 5 Years)

22.8%

Cash / Debt

$42.8 million / $42,000

Other Highly Rated Biotech Stocks

Amgen (NASDAQ:AMGN)

Celgene (NASDAQ:CELG)

Gilead Sciences (NASDAQ:GILD)

CAPS Members Bullish on RGEN Also Bullish on

Johnson & Johnson (NYSE:JNJ)

General Electric (NYSE:GE)

CAPS Members Bearish on RGEN Also Bearish on

Amazon.com (NASDAQ:AMZN)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 97% of the 292 members who have rated Repligen believe the stock will outperform the S&P 500 going forward. These bulls include marcco and All-Star zzlangerhans, who is ranked in the top 0.5% of our community.

Earlier this year, marcco noted that Repligen "enjoys strong, conservative management, a large cash hoard, a significant royalty stream and an interesting pipeline." Our CAPS member concludes: "They could grow by acquisition or be acquired themselves, but they should grow nicely over the next few years."

In a pitch from two weeks ago, zzlangerhans tapped the stock's recent slide as an opportunity to pounce:

Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 20% haircut on a stock already down 15% from recent highs. The company will likely continue to maintain cash flows even through anemic 5M quarterly revenues and lazy spending on the phase IIb trial of (yawn) uridine for bipolar disorder. Is this the most boring baby biotech around? Possibly. So why am I still writing this pitch? Trying to think of a reason why this stock will go back up. OK, because it did before.

What do you think about Repligen, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, and Amazon is a selection of Stock Advisor. The Fool's disclosure policy always gets a perfect score.